Silent progression in disease activity–free relapsing multiple sclerosis
Top Cited Papers
Open Access
- 9 March 2019
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 85 (5), 653-666
- https://doi.org/10.1002/ana.25463
Abstract
Objective Rates of worsening and evolution to secondary progressive multiple sclerosis (MS) may be substantially lower in actively treated patients compared to natural history studies from the pre‐treatment era. Nonetheless, in our recently reported prospective cohort more than half of patients with relapsing MS accumulated significant new disability by the 10th year of follow‐up. Notably, “no evidence of disease activity” at 2‐years did not predict long‐term stability. Here, we determined to what extent clinical relapses and radiographic evidence of disease activity contribute to long‐term disability accumulation. Methods Disability progression was defined as an increase in Expanded Disability Status Scale (EDSS) of 1.5, 1.0 or 0.5 (or greater) from baseline EDSS = 0; 1.0‐5.0; and 5.5 or higher, respectively, assessed from baseline to year 5 (± 1 year) and sustained to year 10 (± 1 year). Longitudinal analysis of relative brain volume loss used a linear mixed model with sex, age, disease duration, and HLA‐DRB1*15:01 as covariates. Results Relapses were associated with a transient increase in disability over one‐year intervals (p = 0.012) but not with confirmed disability progression (p = 0.551). Relative brain volume declined at a greater rate among individuals with disability progression compared to those who remained stable (p < 0.05). Interpretation Long term worsening is common in relapsing MS patients, is independent of relapse activity, and is associated with accelerated brain atrophy. We propose the term silent progression to describe the insidious disability that accrues in many patients who satisfy traditional criteria for relapsing remitting MS.Funding Information
- National Institute of Neurological Disorders and Stroke (R01NS26799)
This publication has 50 references indexed in Scilit:
- Blood neurofilament light chain as a biomarker of MS disease activity and treatment responseNeurology, 2019
- pRNFL as a marker of disability worsening in the medium/long term in patients with MSNeurology Neuroimmunology & Neuroinflammation, 2019
- The 11-year long-term follow-up study from the randomized BENEFIT CIS trialNeurology, 2016
- Factors influencing long-term outcomes in relapsing–remitting multiple sclerosis: PRISMS-15Journal of Neurology, Neurosurgery & Psychiatry, 2015
- An automated tool for detection of FLAIR-hyperintense white-matter lesions in Multiple SclerosisNeuroImage, 2012
- Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteriaAnnals of Neurology, 2011
- Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up studyMultiple Sclerosis Journal, 2010
- Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetateMultiple Sclerosis Journal, 2010
- Impact of multiple sclerosis relapses on progression diminishes with timeNeurology, 2009
- THE NATURAL HISTORY OF MULTIPLE SCLEROSIS: A GEOGRAPHICALLY BASED STUDYBrain, 1989